



Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation

Richard J. Johnson, George L. Bakris, Claudio Borghi, Michel B. Chonchol, David Feldman, Miguel A. Lanasa, Tony R. Merriman, Orson W. Moe, David B. Mount, Laura Gabriella Sanchez Lozada, Eli Stahl, Daniel E. Weiner, and Glenn M. Chertow

Urate is a cause of gout, kidney stones, and acute kidney injury from tumor lysis syndrome, but its relationship to kidney disease, cardiovascular disease, and diabetes remains controversial. A scientific workshop organized by the National Kidney Foundation was held in September 2016 to review current evidence. Cell culture studies and animal models suggest that elevated serum urate concentrations can contribute to kidney disease, hypertension, and metabolic syndrome. Epidemiologic evidence also supports elevated serum urate concentrations as a risk factor for the development of kidney disease, hypertension, and diabetes, but differences in methodologies and impacts on serum urate concentrations by even subtle changes in kidney function render conclusions uncertain. Mendelian randomization studies generally do not support a causal role of serum urate in kidney disease, hypertension, or diabetes, although interpretation is complicated by nonhomogeneous populations, a failure to consider environmental interactions, and a lack of understanding of how the genetic polymorphisms affect biological mechanisms related to urate. Although several small clinical trials suggest benefits of urate-lowering therapies on kidney function, blood pressure, and insulin resistance, others have been negative, with many trials having design limitations and insufficient power. Thus, whether uric acid has a causal role in kidney and cardiovascular diseases requires further study.

Complete author and article information provided before references.

Am J Kidney Dis. 71(6): 851-865. Published online February 26, 2018.

doi: 10.1053/j.ajkd.2017.12.009

© 2018 by the National Kidney Foundation, Inc.

Introduction

The association of serum urate with kidney, cardiovascular (CVD), and metabolic disease has been described since the 19th century, but whether urate metabolism has a role in these diseases is controversial. Experimental and clinical evidence were presented at a Scientific Workshop held by the National Kidney Foundation in September 2016. We present a meeting summary and discuss current controversies.

Serum Urate Regulation

Urate is the end product of nucleic acid metabolism and is also generated during the breakdown of high-energy nucleotides (eg, adenosine triphosphate [ATP]). It is generated intracellularly by xanthine oxidoreductase (XOR) and transported into and exists in the circulation as plasma sodium urate. Intracellular urate concentration likely varies, but may be orders of magnitude lower than it is in serum.¹

In most mammals, serum urate concentrations are low (1-3 mg/dL [60-180 μ M]) due to the enzyme uricase, which degrades uric acid to 5-hydroxyisourate and allantoin. Humans and apes lack uricase due to inactivating mutations that occurred during hominoid evolution,^{2,3} resulting in higher circulating urate concentrations. The lower range of urate concentrations, described in people consuming traditional non-Western diets, is 2 to 4 mg/dL (120-240 μ M).⁴ Serum urate

concentrations are higher in industrialized populations (3-8 mg/dL [180-480 μ M]), reflecting diets richer in purines and fructose (both of which generate urate), greater alcohol intake, increased prevalence of factors that reduce kidney urate excretion (eg, insulin resistance, renal vasoconstriction associated with hypertension, and decreased kidney function),⁴ and interpopulation genetic differences.⁵

In humans, serum urate is excreted by the kidney (two-thirds) and gut (one-third). Some circulating urate is also removed by reaction with oxidants or nitric oxide. Urate production by XOR contributes to serum concentrations,⁶ but the molecular physiology of epithelial urate transport is most relevant to the genetics of hyper- and hypouricemia.⁷

Kidney Urate Excretion

Urate is freely filtered at the glomerulus, followed by reabsorption and secretion in the proximal tubule. However, reabsorption is dominant, resulting in fractional urate excretion \leq 10% (Fig 1).

Urate reabsorption in the proximal tubule occurs by urate/monocarboxylate exchange (Fig 1A). Organic monocarboxylate reabsorption by the apical sodium/monocarboxylate cotransporters SMCT1 and SMCT2^{8,9} results in higher intracellular concentrations of anions that exchange with luminal urate by means of urate-anion exchangers (Fig 1A). Higher concentrations of SMCT substrates (including nicotinate, pyrazinoate,




Figure 1. Transport pathways for urate in proximal tubule cells. (A) Urate reabsorption. Sodium-dependent anion transport by SMCT1 and SMCT2 increases intracellular concentrations of monovalent anions that exchange with luminal urate (URAT1/OAT10). OAT4 appears to exchange urate with divalent anions. GLUT9 is the exit pathway for urate at the basolateral membrane. (B) Urate secretion. Urate enters the cell at the basolateral membrane by exchange with α -ketoglutarate, mediated by OAT1 and OAT3. At the apical membrane, urate is secreted by MRP4, ABCG2, NPT1, and/or NPT4. Figure is copyright Annual Reviews and is reproduced from Mandal and Mount.⁷

lactate, and ketones) in the circulation can lead to hyperuricemia¹⁰⁻¹³ arising from elevated apical uptake of these filtered anions, greater intracellular concentrations in proximal tubular cells, and increased apical urate/anion exchange.¹⁴ In humans, URAT1 is the main apical urate/anion exchanger.¹⁵ The “orphan” organic anion transporter known variously as ORCTL3 or OAT10 also mediates urate/nicotinate and urate/pyrazinoate exchange.¹⁶ Human OAT4 reportedly functions as an apical urate/anion exchanger¹⁷; however, unlike OAT10 and URAT1, OAT4 exchanges urate with divalent organic anions. At the basolateral membrane, GLUT9 (glucose transporter 9) is the sole pathway for urate exit during urate reabsorption. Initially identified as a fructose transporter,¹⁸ GLUT9 functions instead as a urate uniporter.¹⁹

A separate set of transporters function in urate secretion (Fig 1B). At the basolateral membrane, OAT1 and OAT3 transport urate into proximal tubular cells.²⁰ This basolateral uptake is driven by intracellular concentration of divalent anions that exchange with urate by means of OAT1 and OAT3. Uptake of these anions is mediated by the sodium-dependent dicarboxylate transporter NaDC3 (Fig 1B). Efflux at the apical membrane is mediated by the ATP-driven pumps MRP4 (multidrug resistance protein 4)²¹ and ABCG2.^{22,23} There are also electrogenic apical urate transporters (NPT1^{24,25} and NPT4²⁶) that function in secretion.

Gut Urate Excretion

Urate is also transported in the gut, where as much as one-third can be degraded by uricolytic bacteria. Mechanisms for urate transport in the gut are uncertain, but both GLUT9 and ABCG2 transport urate into the gut, and knockout of intestinal GLUT9 can cause hyperuricemia.²⁷ Knockout of

ABCG2 results in hyperuricemia and “overload” uricosuria.²⁸

Definition of Hyperuricemia

Hyperuricemia is defined as serum urate concentrations > 7 mg/dL (>420 μ M) in men and >6 mg/dL (>360 μ M) in women. For children and adolescents, a concentration \geq 5.5 mg/dL (\geq 330 μ M) is considered abnormal.²⁹ Serum urate concentrations are lower in premenopausal women due to the uricosuric effects of estrogen, and following menopause, urate increases to concentrations similar to those observed in men. The concentration of 7 mg/dL (420 μ M) is viewed as abnormal because it nearly matches the solubility of urate in water; however, urate is more soluble in plasma and concentrations may be >10 mg/dL (>600 μ M) without crystal deposition.

In gout, hyperuricemia results from both dietary purine excess³⁰ and reduced urinary urate excretion. In the steady state, urinary excretion reflects the rate of production; notably, the fractional excretion of urate can increase rapidly in response to a purine load.³⁰

Biological Actions of Urate

Antioxidant Effects

Urate can function as an antioxidant, especially in the extracellular environment.³¹ Urate reacts with superoxide to generate allantoin and with peroxynitrite to form triuret. These effects may be important in neurologic disease, in which acute administration of urate reduces neurologic injury in models of ischemic stroke³² or multiple sclerosis.³³ In contrast, the reaction of urate with peroxynitrite generates aminocarbonyl and triuretcarbonyl radicals,³⁴ and the reaction with myeloperoxidase generates the pro-oxidant urate hydroperoxide.³⁵

Immune Effects

Urate may aid the immune response by release from dying cells, facilitating recognition of apoptotic cells by dendritic cells and activation of CD8 cells.^{36,37}

Proinflammatory Effects

Although urate is an extracellular antioxidant, intracellular urate functions as a pro-oxidant, stimulating reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.³⁸⁻⁴¹ The effects of exogenous urate on cells can be prevented if cellular uptake of urate is prevented by probenecid (an organic anion transport inhibitor). Likewise, biological effects of endogenously produced urate can be prevented by blocking its synthesis with XOR inhibitors (XORIs).^{39,42}

Urate exerts autocrine, paracrine, and endocrine effects. High intracellular urate concentrations stimulate mitogen activated protein kinases, proinflammatory transcription factors (nuclear factor κ B [NF- κ B]), growth factors, vasoconstrictive substances (angiotensin II, thromboxane, and endothelin), chemokines, and mitochondrial dysfunction.^{39,43-45} Urate also reduces endothelial nitric oxide bioavailability by a variety of mechanisms and inhibits endothelial cell proliferation and migration.^{44,46-48} High urate concentrations induce proximal tubular dysfunction with release of inflammatory chemokines, vascular cell muscle proliferation, fat synthesis in hepatocytes, oxidative stress in islet cells, and decreased adiponectin synthesis in adipocytes.^{39,49-53}

Models of Hypertension and Kidney Injury

The classic model of hyperuricemia in the rat involves administering a uricase inhibitor (oxonic acid) to double or triple serum urate concentration. Hyperuricemic rats develop modest hypertension mediated by activation of renal and systemic renin-angiotensin-aldosterone systems (RAAS), oxidative stress, and loss of endothelial nitric

oxide.⁵⁴⁻⁵⁷ Over time, microvascular and inflammatory changes in the kidney drive hypertension independent of serum urate concentrations.⁵⁸ Afferent arteriolar disease also results in impaired renal autoregulation with glomerular hypertension while simultaneously reducing renal blood flow.⁵⁹ These effects can both cause chronic kidney disease (CKD)⁶⁰ and accelerate existing CKD⁴³ with histologic and renal hemodynamic features similar to those observed in persons with longstanding gout and/or hypertension.⁶¹ Experimental studies also confirmed a role of urate in animal models of diabetic kidney disease, calcineurin inhibitor nephrotoxicity, and acute kidney injury (AKI) (Table 1).^{43,54,55,59,62-64,66-76}

Although many effects of urate appear to be mediated by its intracellular action, kidney injury in humans can occur with hyperuricosuria, especially in the setting of urate crystalluria and acidic urinary pH. Soluble urate and urate crystals activate inflammasomes, causing local inflammation and tubular injury.^{77,78} Hyperuricosuria and/or hyperuricemia may also play a role in AKI (eg, rhabdomyolysis and radiocontrast administration).^{74,79,80} Figure 2 summarizes mechanisms by which urate induces kidney damage through crystal-independent and crystal-dependent mechanisms. Figure 3 shows a possible mechanism for urate-induced hypertension.

Fructose and Metabolic Syndrome

Fructose is distinct from most energy sources in its ability to induce features of metabolic syndrome.⁸¹ Experimental studies suggest that this occurs secondary to a decrease in ATP concentrations during fructose metabolism that leads to intracellular urate generation, mitochondrial oxidative stress, and inhibition of adenosine monophosphate (AMP)-activated protein kinase.^{39,52,82,83} Urate also stimulates aldose reductase (which can lead to more fructose generation) and fructokinase (which amplifies the pathway).^{53,84} Reducing serum and intracellular urate

Table 1. Experimental Models in Which Lowering Serum Urate Prevents or Improves Kidney Injury

Model	Hyperuricemia	UA-Lowering Drug	References
Oxonic acid (rat)	Yes	Allopurinol, febuxostat, benzbromarone, thiazolidopyrimidin-5-one analogue	54, 55, 62-64
Oxonic acid + 5/6 nephrectomy (rat)	Yes	Allopurinol, febuxostat	43, 59, 65
Oxonic acid + cyclosporine (rat)	Yes		66
Tacrolimus-induced nephrotoxicity (rat)	Yes	Febuxostat	67
Cyclosporine-induced nephrotoxicity (rat)	Yes	Allopurinol, benzbromarone	68
Diabetic nephropathy associated with type 1 diabetes (rat)	No	Febuxostat	69
Diabetic nephropathy associated with type 2 diabetes (rat, mouse, in vitro culture)	Yes	Febuxostat, allopurinol	70-72
Spontaneously hypertensive rat	Not reported	Allopurinol	73
Rhabdomyolysis-induced AKI (rat)	Not reported	Allopurinol	74
Oxonic acid + cisplatin-induced AKI (rat)	Yes	Rasburicase	49
Unilateral ureteral obstructive nephropathy (rat)	Yes	Febuxostat	75
Renal ischemia-reperfusion injury (rat)	No	Febuxostat	76

Abbreviations: AKI, acute kidney injury; UA, uric acid.




Figure 2. Potential mechanisms by which urate may cause kidney disease. Urate may induce renal damage in its soluble (crystal-independent) or crystal form. After entering renal cells, soluble uric acid can activate various cascades and responses that lead to damaging inflammatory, proliferative, and maladaptive changes in glomeruli and the tubulointerstitium (TI). Crystalline uric acid seems to be confined to the TI, where it may elicit similar changes. Abbreviation: VSM, vascular smooth muscle.

concentrations has been found to block features of metabolic syndrome in fructose-dependent and -independent models.^{85,86} The side effects of thiazides to induce features of metabolic syndrome could also be prevented by lowering serum urate concentrations with allopurinol.⁸⁷

The observation that knocking down the urate transporter GLUT9 in the intestine causes hyperuricemia and metabolic syndrome that can be ameliorated by XORIs further supports a role for uric acid in the causality of

metabolic syndrome.²⁷ In contrast, with hepatic knockout of GLUT9, hyperuricemia develops without hypertension or metabolic syndrome.⁸⁸

An Evolutionary Perspective

The observation that parallel inactivating mutations occurred in uricase during the Oligocene and Miocene epochs in the ancestors of humans and great apes and also in lesser apes suggests a survival advantage to higher serum urate concentrations.^{2,3} Various hypotheses have been proposed, including the possibility that urate may have carried a survival advantage as an antioxidant³¹ or as a means to help increase blood pressure (BP) during a period when salt intake was low⁵⁸ or to help store fat during a time of global cooling when fruit was less available.⁸⁹ Viewed in this context, the uricase mutation may have functioned as a “thrifty gene,” being protective during periods of starvation in the past, but harmful with ample access to food.




Figure 3. Mechanism of hyperuricemia-induced hypertension. Hyperuricemia-induced hypertension has been proposed to be a consequence of the effect of serum and/or intracellular urate to stimulate the renin-angiotensin-aldosterone system, lower endothelial nitric oxide, induce oxidative stress, and stimulate vascular smooth muscle cell proliferation, resulting in systemic and renal vasoconstriction and arteriosclerosis leading to hypertension.

Epidemiology

Epidemiologic Studies

Many studies have evaluated whether serum urate is independently associated with CKD, hypertension, and metabolic syndrome/type 2 diabetes.^{90,91} Many studies are limited by disparate covariate adjustment strategies and exposure and outcome definitions, which introduce uncertainty when attempting to integrate evidence. Nevertheless, longitudinal studies have shown that elevated serum urate concentration is independently associated with hypertension in 22 of 23 published studies, including

2 meta-analyses.⁹²⁻⁹⁴ The relation of serum urate with the development of hypertension meets Bradford Hill criteria for a likely causal relation (Box 1).^{29,54,62,95-97}

In 23 of 24 published studies, including meta-analyses,⁹⁸⁻¹⁰⁰ higher serum urate concentrations are independently associated with metabolic syndrome and type 2 diabetes in men, women, or both and may also be independently associated with obesity.¹⁰¹ Serum urate concentration was reported to independently predict incident CKD in 17 of 18 published studies and in meta-analyses in people with and without diabetes.¹⁰²⁻¹⁰⁷ However, serum urate is not consistently associated with progression of CKD in patients with pre-existing CKD

(reviewed in¹⁰⁸). Hyperuricemia also predicts AKI following surgery or radiocontrast exposure.^{79,109}

In contrast, serum urate concentration is not consistently associated with CVD,¹¹⁰⁻¹¹² likely reflecting complex causal linkages among potential risk factors used in multivariable analysis.¹¹³ Nevertheless, one study found hyperuricemia to be associated with hypertension, obesity, and CKD in Japanese adults who at baseline did not have elevated Quetelet (body mass) index, had normal BP, and had normal glucose tolerance.¹¹⁴

A major problem with these epidemiologic studies is that serum urate concentrations are affected by kidney function, and the relationship may be subject to confounding by other factors.^{113,115,116} A confounder is associated with both the exposure and the outcome, but does not constitute the causal pathway between exposure and outcome. Epidemiologic studies attempt to account for confounding through multivariable adjustment and other strategies; however, if there is residual confounding, the association between serum urate and CKD may be significant even in the absence of causality.¹¹³ For example, if the true risk factor for CKD were oxidative stress (which is not directly measured) rather than hyperuricemia, the presence of hyperuricemia as a proxy for oxidative stress could lead to the incorrect conclusion that hyperuricemia causes CKD. Box 2 summarizes factors affecting the association of urate with outcomes in observational studies and clinical trials.

Box 1. Bradford Hill Criteria for Causality: Urate and Hypertension

- Strength** (effect size): An elevated serum uric acid consistently predicts a 1.5- to 2-fold increased risk for hypertension within 5-10 y.⁹²
- Consistency** (reproducibility): An elevated serum uric acid independently predicts the development of hypertension in 22 of 23 studies.⁹²
- Specificity**: The risk for developing hypertension in those with elevated serum urate level persists after controlling for other cardiovascular risk factors. In adolescents, new-onset essential hypertension is associated with an elevated serum urate (≥ 5.5 mg/dL) in 90% of cases; by contrast, hyperuricemia occurs in just 30% of those with secondary hypertension and is rare in normotensive and white-coat hypertensive adolescent patients.²⁹
- Temporality**: Although not all individuals with hypertension have hyperuricemia, an elevated serum urate frequently precedes the development of hypertension, and in adolescents, 90% with primary hypertension have been reported to have hyperuricemia.⁹² These data are most consistent with hyperuricemia being a major cause of hypertension in adolescents.
- Biological gradient**: A linear relationship is observed between serum uric acid and level of blood pressure in adolescents with primary hypertension ($r=0.80$).²⁹
- Plausibility**: Experimental studies found that hyperuricemia in rats results in hypertension that is mediated by activation of the renin-angiotensin system, induction of oxidative stress, and inhibition of endothelial function.⁵⁴⁻⁵⁷
- Coherence**: Lowering serum urate in hyperuricemic hypertensive adolescents was observed to correct blood pressure in 86% of cases whose serum urate was lowered to <5 mg/dL.⁹⁶ This was also found to be associated with a reduction in plasma renin activity consistent with experimental studies that the hypertension is dependent on the renin-angiotensin system.^{54,55}
- Experiment**: Rats with experimental hyperuricemia develop hypertension that can be corrected by either a xanthine oxidase inhibitor or an uricosuric agent.^{54,62}
- Analogy**: Experimentally one can also induce hypertension by stimulation of the renin-angiotensin system, blocking endothelial nitric oxide synthase, or inducing oxidative stress, all mechanisms mediated by uric acid.⁹⁷

Mendelian Randomization Studies

Genome-wide association studies (GWAS) have identified approximately 30 loci controlling serum urate.^{117,118} The loci with the strongest effects encode uric acid transporters (eg, GLUT9, ABCG2, and URAT1)^{117,118} or regulatory transporter-associated proteins (eg, PDZK1).^{117,119} In general, loss-of-function mutations in reabsorptive urate transporters cause hypouricemia,^{15,117,120-123} whereas loss-of-function mutations in secretory transporters result in hyperuricemia.^{23,26,28} Other loci with weaker effects encode genes involved in glycolysis, consistent with a role for hepatic metabolism in urate homeostasis. However, for most loci, causal genes and causal variants have not been

Box 2. Factors Affecting the Association of Serum Urate With Kidney and Cardiovascular Outcomes in Epidemiologic Studies

- Heterogeneity of patients
- Heterogeneity of baseline GFR
- Heterogeneity of risk factors
- Limitations with GFR prediction
- Competing risks (multiple hits) and competing outcomes
- Varying outcome definitions and lack of a core outcomes set
- Varying exposure definitions
- Varying follow-up time
- Adjusting for factors in the causal pathway
- Unmeasured and unadjusted confounding

Abbreviation: GFR, glomerular filtration rate.

identified. Predictably, many of the urate-controlling loci are associated with gout.^{117,124,125}

The identification of genetic polymorphisms that influence serum urate concentrations has allowed investigation of whether these polymorphisms also increase the risk for hypertension or kidney disease. Specifically, large populations in which GWAS have been performed can be used to develop a “genetic score” to identify individuals with genetic predisposition to hyperuricemia and gout (as evidence for validation), CKD, hypertension, and type 2 diabetes. Because persons with urate-raising and urate-lowering genetic variants have been exposed to these variants since conception and provided that genetic variants are not themselves associated with confounders or do not exhibit pleiotropic effects, these Mendelian randomization studies can mitigate confounding.¹²⁶

Using this approach, many adequately powered studies have been unable to find associations between a genetic urate score with hypertension,^{117,127} type 2 diabetes,¹²⁷⁻¹²⁹ or the development of CKD,^{127,130,131} arguing against a causal role of urate in these disease states. However, the absence of associations in these studies does not conclusively dismiss causality. First, intracellular urate drives its metabolic and vascular effects (rather than extracellular concentrations or crystal deposition), and polymorphisms that affect serum urate may not have the same effect on intracellular and hepatic urate.^{27,88,132} Second, environment and/or diet can influence the effects that genetic polymorphisms exert on urate disposition.^{133,134} Third, most published studies focus on polymorphisms involved in renal urate handling without considering alternative pathways. For example, genetic polymorphisms of XOR have been linked with CVD.^{135,136} Finally, the inability to show an association does not mean that lowering serum urate concentrations may not have beneficial effects on hypertension or CKD; inhibitors of the renin-angiotensin system (RAAS), for example, are beneficial in the management of hypertension and CKD despite GWAS failing to identify genetic polymorphisms of the RAAS associated with hypertension and CKD.

Other Mendelian randomization studies have identified associations of genetic polymorphisms that influence serum urate concentrations with hypertension, obesity, metabolic syndrome, CVD, or CKD.¹³⁷⁻¹⁴³ These studies differ from others because they either focus on more homogeneous populations, such as Italian^{144,145} or Native American populations,^{139,146} or assess interactions of the genetic score with potential confounders, such as body mass index¹⁴⁷ or asymmetric dimethylarginine concentrations.¹³⁸

GWAS Loci Predicting Both CKD and Serum Urate Concentration

A GWAS has identified approximately 50 loci associated with estimated glomerular filtration rate (eGFR) and

CKD.¹⁴⁸ Of these, 9 are also associated with serum urate concentrations (Table 2), none of which encode urate transporters. Interestingly, patterns are the same for most shared loci, suggesting that (as yet unidentified) genetic variants associated with serum urate and kidney function are likely to be the same. However, there is inconsistency in the direction of effect, with the serum urate-increasing allele associated with better kidney function in some cases and worse kidney function in others. These data suggest that shared pathologic mechanism(s) between effectors of kidney function and determination of hyperuricemia further complicating interpretation.

Clinical Trials

Hypertension

Studies of the role of urate in hypertension have largely focused on children and adolescents, reflecting experimental studies showing that hyperuricemia has its greatest effect on BP early in life, before kidney microvascular and inflammatory changes occur.^{55,58} Adolescents with primary hypertension have elevated serum urate concentrations (>5.5 mg/dL) in nearly 90% of cases, correlating directly with systolic BP (SBP).²⁹ A small pilot study reported that lowering serum urate concentration to <5.0 mg/dL (<300 μM) normalized BP in 86% of patients compared to 3% during the placebo phase.⁹⁶ A double-blind randomized study in which obese prehypertensive adolescents were given placebo, probenecid (a uricosuric), or allopurinol (an XORI) showed a significant decrease in BP in both the probenecid- and allopurinol-treated groups, and lowering serum urate concentration was associated with less weight gain.¹⁴⁹ The therapeutic equivalence of probenecid and allopurinol suggests that urate-lowering mediated the

Table 2. Shared Loci for eGFR and Serum Urate Control

Locus (function)	SNP Association	Urate	eGFR
<i>A1CF</i> (regulation of lipoprotein synthesis)	Same	↑	↑
<i>BCAS3</i>	Same, additional signal in eGFR	↑	↑
<i>GCKR</i> (glycolysis)	Same	↑	↑
<i>INHBC</i>	Same	↑	↓
<i>LRP2</i>	Different	—	—
<i>PRKAG2</i> (energy)	Same	↑	↓
<i>STC1</i>	Same	↑	↓
<i>UBE2Q2</i>	Same	↑	↓
<i>VEGFA</i>	Same	↑	↓

Note: Arrows indicate whether the effect allele of the most associated SNP at each locus increases or decreases urate concentrations or eGFR.

Abbreviations: *A1CF*, apolipoprotein B messenger RNA editing enzyme, catalytic polypeptide 1 complementation factor; *BCAS3*, breast carcinoma amplified sequence 3; eGFR, estimated glomerular filtration rate; *GCKR*, glucokinase regulatory protein; *INHBC*, inhibin beta C chain; *LRP2*, lipoprotein-related protein 2; *PRKAG2*, protein kinase adenosine-monophosphate-activated non-catalytic subunit gamma 2; SNP, single-nucleotide polymorphism; *STC1*, stanniocalcin 1; *UBE2Q2*, ubiquitin-conjugating enzyme E2 Q2; *VEGFA*, vascular endothelial growth factor A.

effect. A third double-blind placebo-controlled study in older (>65 years) patients after ischemic stroke who had prehypertension found that treatment with allopurinol in patients with normal serum urate concentrations resulted in a decrease in clinically assessed SBP and central SBP and a reduction in carotid intimal thickness compared to placebo.¹⁵⁰ Allopurinol lowered SBP and diastolic BP in obese middle-aged adults with prehypertension and modestly elevated serum urate concentrations (6.0–6.2 mg/dL [360–372 μM]).¹⁵¹ One study of asymptomatic hyperuricemia (serum urate ≥ 8 mg/dL [≥480 μM]) found a decrease in SBP with improvement in eGFR following allopurinol treatment compared to placebo.¹⁵² In contrast, 2 double-blind placebo-controlled trials found that lowering serum urate concentrations in patients with modestly elevated serum urate concentrations (6–7 mg/dL [360–480 μM] range) did not lower BP, although interpretation is limited by the fact that the mean blood pressure of participants was in the normotensive range prior to starting therapy.^{153–155}

Chronic Kidney Disease

Small studies have reported that treatment with XORIs can slow CKD progression.^{156–161} A double-blind placebo-controlled trial randomly assigned 93 hyperuricemic patients with CKD stage 3 or higher to febuxostat (or placebo) for 6 months.¹⁵⁸ Febuxostat attenuated the decline in kidney function, with 38% showing a >10% decline in eGFR versus 54% in the placebo group ($P = 0.004$). Febuxostat also lowered SBP (−13 vs −4 mm Hg).¹⁵⁸

Two randomized trials reported that lowering serum urate concentrations with allopurinol could slow CKD progression in patients with CKD stage 3,^{156,157} with one trial showing a reduction in cardiovascular events.^{157,162} In another trial, 109 hyperuricemic patients with CKD stage 3 or higher and who had previously undergone cardiac surgery were randomly assigned to allopurinol or febuxostat for 6 months. Febuxostat reduced serum urate concentrations and led to favorable effects on SBP, eGFR, and albuminuria.¹⁶³ Post hoc analyses of other studies also suggest beneficial effects of lowering serum urate concentrations with febuxostat and/or allopurinol on kidney function in patients with gout and CKD stage 2.^{159,160} In contrast, 3 studies (in patients with diabetic nephropathy,¹⁶⁴ immunoglobulin A nephropathy,¹⁶⁵ and stage 3 CKD¹⁶⁶) reported no change in eGFR with allopurinol/febuxostat. Of note, these studies were either limited in duration (12 weeks)^{164,166} or enrolled patients with stable CKD.¹⁶⁵ Interestingly, beneficial effects on BP^{165,166} and albuminuria^{164,166} were still observed.

Acute Kidney Injury

Several studies have investigated whether lowering serum urate concentrations may prevent AKI. One clinical trial of hyperuricemic patients undergoing cardiac surgery reported that urate lowering with

rasburicase resulted in lower concentrations of the kidney tubular injury marker urine neutrophil-associated lipocalin but no difference in postoperative serum creatinine concentrations.¹⁶⁷ In 2 trials comparing hydration to hydration plus allopurinol in the prevention of radiocontrast nephropathy, none of the 169 participants receiving allopurinol with hydration developed AKI (defined as worsening of serum creatinine by >25%) compared to 35 of the 170 (20%) participants receiving saline solution alone.^{168,169}

Insulin Resistance and Metabolic Syndrome

Urate-lowering therapy in hyperuricemic patients has been reported to improve insulin resistance or fasting glucose concentrations.^{170–172} A double-blind crossover trial that randomly assigned patients to benzbromarone or placebo found that patients with heart failure and hyperuricemia showed an improvement in insulin resistance (as assessed by Homeostatic Model Assessment of Insulin Resistance [HOMA-IR]) after 8 weeks.¹⁷⁰ In contrast, another study found that allopurinol attenuated the increase in BP resulting from a high-fructose diet, but did not improve insulin resistance.¹⁷³

Finally, one study randomly assigned patients with type 2 diabetes and asymptomatic hyperuricemia ($n = 176$) to allopurinol or placebo for 3 years. The allopurinol-treated group had lower SBP and diastolic BP, less worsening of HOMA-IR and serum triglyceride concentration, lower albuminuria, higher eGFR, and fewer cases of new-onset diabetic nephropathy (defined as urine albumin excretion > 200 μg/min [4.9% vs 10%]).¹⁶¹

Additional Issues With Use of XORIs

XORIs are ideal urate-lowering agents because they block production and will reduce both intra- and extracellular urate. In contrast, uricosuric agents may block urate uptake into cells,^{38,44} but will not block intracellular urate production, such as occurs during fructose metabolism. Because most of the cardiovascular and kidney effects of urate are thought to be mediated by intracellular urate, XORIs are thought to be superior to uricosurics in blocking urate's biological effects. Nevertheless, interpretation of studies using XORIs are confounded because the conversion of hypoxanthine and xanthine to urate by XOR results in the production of oxidants. Thus, blocking XOR also reduces oxidative stress that may be independent of urate. One study reported that XORIs could improve endothelial dysfunction, whereas probenecid could not,¹⁷⁴ and other studies also suggest that XOR may also be induced by oxidants generated from other sources (such as from mitochondria or NADPH oxidase) to amplify local oxidative stress.¹⁷⁵ Nevertheless, the benefit of XOR inhibition on fat accumulation in cultured hepatocytes can be blocked by adding urate back to the incubation mixture.³⁹ Uricosuric agents have also been reported to improve BP and insulin resistance in 2 studies.^{149,170}

Summary

When considering clinical trials of urate-lowering therapy in hypertension, it appears that the effects of urate-lowering therapy on BP are most likely to be observed among patients with hyperuricemia (especially if serum urate is >8 mg/dL [$>476 \mu\text{M}$]) when baseline SBP is >130 mm Hg and GFR is normal. Likewise, when considering trials of urate-lowering therapy and effects on CKD progression, it appears there may be benefits in patients with hyperuricemia and in longer duration trials sufficient to see non-hemodynamically-mediated changes in eGFR.

Angiotensin-converting enzyme (ACE) inhibitors and other blockers of the RAAS may impact the association between urate and kidney outcomes, with experimental studies and clinical studies of humans suggesting that hyperuricemia affects both blood pressure and kidney function in part by activation of the RAAS.^{41,55,96} In this regard, withdrawal of allopurinol in one study of patients with CKD resulted in worsening of BP and more rapid CKD progression only in patients who were not concurrently treated with ACE inhibitors.¹⁷⁶ In addition to the possibility that lowering urate concentrations might down-regulate the RAAS, the angiotensin receptor blocker losartan can also lower serum urate concentration by increasing urine urate excretion. Hence, studies in which agents that block the RAAS are used may obscure effects of urate-lowering therapy and vice versa. Because RAAS blockade is commonly used in CKD, a trial of urate-lowering therapy may be primarily addressing whether

decreasing serum urate concentrations provides benefit above and beyond that provided by RAAS inhibitors.

The safety of urate-lowering therapies must be considered. In rare cases, allopurinol can cause a hypersensitivity syndrome that resembles Stevens-Johnson syndrome, especially in persons with the HLA-B*58 serotype.¹⁷⁷ There has also been some concern that use of febuxostat may be associated with increased cardiovascular risk compared to allopurinol, resulting in a recent US Food and Drug Administration alert.^{178,179} Uricosuric agents may increase the risk for kidney stones; in phase 3 trials, lesinurad caused transient increases in serum creatinine concentrations when used at high doses, and without concomitant XORIs.¹⁸⁰

In summary, although pilot clinical trials of urate-lowering therapy suggest potential benefits in the treatment of hypertension and prevention of kidney disease and CVD, they have been limited in size and power and have generally used intermediate or surrogate end points. Comparisons of urate-lowering therapy and placebo on top of standard therapies (including RAAS inhibitors) are underway (Table 3) or planned (Box 3) in several adequately powered trials with hard cardiovascular and/or kidney end points. In particular, the Preventing Early Renal Function Loss (PERL) Consortium is randomly assigning 400 adults with type 1 diabetes, mild to moderate CKD with albuminuria, and serum urate concentrations ≥ 4.5 mg/dL to allopurinol or placebo, with allopurinol titrated to reduce serum urate concentrations to <4.5 mg/dL. The primary outcome of

Table 3. Summary of Randomized Clinical Trials in the Field of Serum Urate and Cardiovascular Diseases

CV field	Intervention	Primary Outcomes	ID No. and Status
BP control	Febuxostat vs allopurinol	Clinic BP and ABPM	NCT01701622 ^a ; terminated (unable to enroll participants)
Coronary endothelial dysfunction	Febuxostat vs placebo	Coronary flow	NCT01763996 ^a ; completed
BP control	Febuxostat vs placebo	ABPM	NCT01496469 ^a ; completed
Exercise tolerance in chronic angina	Febuxostat vs placebo	ETT	NCT01549977 ^a ; terminated
Vascular structure and function (FORWARD)	Febuxostat vs allopurinol	Carotid-femoral PWV	EudraCT 2014-5567-33; enrollment closed
New-onset metabolic syndrome (FAST)	Febuxostat vs placebo	Insulin resistance and features of metabolic syndrome	NCT01654276 ^a ; ongoing
BP and CV complications (CARES)	Febuxostat vs allopurinol	MACE	NCT01101035 ^a ; ongoing
Treatment of CHD (ALL-HEARTY)	Allopurinol vs placebo	MACE	EudraCT 2013-003559-39; ongoing
Cerebrovascular protection (XILO-FIST)	Allopurinol vs placebo	White matter protection	NCT02122718 ^a ; starting recruitment
Major CV diseases (FREED)	Febuxostat vs placebo	MACE	NCT01984749 ^a ; ongoing

Abbreviations: ABPM, ambulatory blood pressure monitoring; BP, blood pressure; CHD, coronary heart disease; CV, cardiovascular; ETT, exercise tolerance testing; MACE, major adverse cardiovascular events; PWV, pulse wave velocity.

^aClinicalTrials.gov.

Box 3. Potential RCTs Assessing Urate-Lowering for Kidney Disease and Cardiovascular Disease Benefits**RCT #1: General Population**

Population: Patients with asymptomatic hyperuricemia (≥ 6 mg/dL), HTN, and additional CV or CKD risk

Intervention: XOI fixed or titrated dose, probenecid or lesinurad fixed or titrated dose, placebo

Outcomes: GFR slope, BP change (no. of medications), 30% decline in eGFR; CV outcomes; AEs; urine ACR

Duration: 5 y with a priori–defined longer term posttreatment follow-up

RCT #2: CKD Population

Population: Asymptomatic hyperuricemia (≥ 6 mg/dL), HTN, and eGFR < 60 mL/min/1.73 m² with albuminuria or

eGFR < 45 mL/min/1.73 m² regardless of albuminuria

Intervention: Allopurinol/febuxostat fixed or titrated dose, placebo

Outcomes: 30% decline in eGFR; composite of ESRD, kidney failure death, or 50% decline in eGFR; CV outcomes; AEs;

urine ACR

Duration: 4 y with a priori–defined longer term posttreatment follow-up

RCT #3: AKI Risk Population

Population: Patients at risk for AKI (planned major CV surgery)

Intervention: Allopurinol/febuxostat fixed dose preprocedure for several weeks

Outcomes: AKIN stage 3, AKIN stage 1

Abbreviations: ACR, albumin-creatinine ratio; AE, adverse event; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; BP, blood pressure; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; (e) GFR, (estimated) glomerular filtration rate; ESRD, end-stage renal disease; HTN, hypertension; RCT, randomized clinical trial; XOI, xanthine oxidase inhibitor.

this 3-year intervention trial is GFR measured using iohexol, assessed 2 months after intervention washout to diminish the influence of possible hemodynamic effects.¹⁸¹

Conclusions

Though hyperuricemia was considered a potential cause of hypertension by Mahomed in the 1870s, after 140 years, the potential causal role of urate in kidney disease and hypertension is still hotly debated. Hyperuricemia is a biomarker for kidney and cardiovascular risk, but serum urate concentration also increases as GFR decreases. Although serum urate concentration is a strong independent risk marker for incident CKD and hypertension, Mendelian randomization studies do not support urate as a causal factor in these conditions. At this time, in concordance with a recent Cochrane review,¹⁸² and given potential toxicities of current treatments, we cannot recommend routine treatment of hyperuricemia in persons with hypertension, kidney disease, or metabolic syndrome/type 2 diabetes. Rather, we must await the results of well-designed and adequately powered clinical trials.

Article Information

Authors' Full Names and Academic Degrees: Richard J. Johnson, MD, George L. Bakris, MD, Claudio Borghi, MD, Michel B. Chonchol, MD, David Feldman, PhD, Miguel A. Lanaspa, PhD, Tony R. Merriman, PhD, Orson W. Moe, MD, David B. Mount, MD, Laura Gabriella Sanchez Lozada, PhD, Eli Stahl, PhD, Daniel E. Weiner, MD, MS, and Glenn M. Chertow, MD, MPH.

Authors' Affiliations: University of Colorado, Denver, CO (RJJ, MBC, MAL); University of Chicago Medicine, Chicago, IL (GLB); University of Bologna, Bologna, Italy (CB); National Kidney Foundation, New York City, NY (DF); University of Otago, Dunedin, NZ (TRM); University of Texas Southwestern Medical Center, Dallas, TX (OWM); Brigham and Women's Hospital, Harvard Medical School, Boston, MA (DBM); Instituto Nacional de Cardiologia, Ignacio Chávez, Mexico City, Mexico (LGSL); Mount Sinai School of Medicine, New York City, NY (ES); Tufts Medical Center, Boston, MA (DEW); and Stanford University, Stanford, CA (GMC).

Address for Correspondence: Glenn M. Chertow, MD, Stanford University School of Medicine, 1070 Arastradero Rd, Ste 313, Palo Alto, CA 94304. E-mail: gchertow@stanford.edu

Support: We thank Takeda Pharmaceuticals, Inc for funding the symposium; of note, Takeda did not participate in the discussions and had no influence on the published proceedings.

Financial Disclosure: Dr Johnson is an inventor on patents related to lowering uric acid as it relates to BP, insulin resistance, and diabetic kidney disease and has equity in XORT Therapeutics, Inc and Colorado Research Partners LLC, which are startup companies interested in developing novel xanthine oxidase inhibitors and fructokinase inhibitors, respectively. Dr Johnson has also received honoraria from Danone and Astra Zeneca and is on the Scientific Board of Kibow, Inc. Dr Borghi received honoraria from Menarini Int, Takeda, Teejin, and Astrellas Drug Company and is on the Scientific Board of Menarini Int and Grunenthal. Dr Bakris is the principal investigator of the FIDELIO trial (Bayer) and on the steering committee of 2 other renal outcome trials, SONAR (AbbVie) and CREDESCENCE (Janssen), and 1 resistant hypertension trial, CALM-2 (Vascular Dynamics) and is a consultant for Merck and Relypsa. Dr Chertow has consulted for Astra Zeneca (formerly Ardea Biosciences). Dr Sanchez Lozada receives research support from Danone Research and Kibow Biotech, Inc and is a member of Colorado Research Partners, LLC. Dr Mount has involvement with UpToDate (hypouricemia card), Horizon Pharma (consultant), Kowa Pharmaceuticals (consultant), and Astra Zeneca (grant support). Dr Moe did consultations for AbbVie, Allena, Ardelyx, Genzyme-Sanofi, Relypsa, and Tricida. Dr Merriman has received research funding and has consulted with Ardea Biosciences and Ironwood Pharmaceuticals. The other authors declare that they have no relevant financial interests.

Acknowledgements: The authors recognize the following conference participants, whose contributions to breakout groups and to the lively discussion throughout the conference rendered the manuscript more substantive: Angelo Chamorro, David Cherney, Hyon Choi, Jesse Dawson, Alessandro Doria, Lawrence Edwards, Ahsan Ejaz, Mehdi Fini, John Forman, Eric Gaucher, Diana Jalal, Duk-Hee Kang, Masanari Kuwabara, Jose Luno, Magdalena Madero, Marilda Mazzali, Takahiko Nakagawa, Alan C. Pao, Roberto Pontremoli, Carlos A. Roncal, Kenneth G. Saag, Mark Stewart Segal, Jasvinder Singh, Janet Snell-Bergeon, Robert Terkeltaub, Adrienne Tin, and Saroja Voruganti. The members of the Symposium also acknowledge the important contributions of Dr Christopher King, who died prematurely after the symposium, and thank Dr Saroja Voruganti for critical review of the manuscript and Dr Eli Stahl for contributions to [Table 2](#).

Peer Review: Received September 15, 2017. Evaluated by 2 external peer reviewers, with direct editorial input from an Associate Editor and a Deputy Editor. Accepted in revised form December 3, 2017.

References

- Kim KM, Henderson GN, Ouyang X, et al. A sensitive and specific liquid chromatography-tandem mass spectrometry method for the determination of intracellular and extracellular uric acid. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2009;877(22):2032-2038.
- Kratzer JT, Lanaspas MA, Murphy MN, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. *Proc Natl Acad Sci U S A*. 2014;111(10):3763-3768.
- Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. *Mol Biol Evol*. 2002;19(5):640-653.
- Johnson RJ, Tittle S, Cade JR, Rideout BA, Oliver WJ. Uric acid, evolution and primitive cultures. *Semin Nephrol*. 2005;25(1):3-8.
- Merriman TR. Population heterogeneity in the genetic control of serum urate. *Semin Nephrol*. 2011;31(5):420-425.
- Gondouin B, Jourde-Chiche N, Sallee M, et al. Plasma xanthine oxidase activity is predictive of cardiovascular disease in patients with chronic kidney disease, independently of uric acid levels. *Nephron*. 2015;131(3):167-174.
- Mandal AK, Mount DB. The molecular physiology of uric acid homeostasis. *Annu Rev Physiol*. 2015;77:323-345.
- Coady MJ, Chang MH, Charron FM, et al. The human tumour suppressor gene SLC5A8 expresses a Na⁺-monocarboxylate cotransporter. *J Physiol*. 2004;557(pt 3):719-731.
- Srinivas SR, Gopal E, Zhuang L, et al. Cloning and functional identification of slc5a12 as a sodium-coupled low-affinity transporter for monocarboxylates (SMCT2). *Biochem J*. 2005;392(pt 3):655-664.
- Goldfinger S, Klinenberg E Jr, Seegmiller JE. Renal retention of uric acid induced by infusion of beta-hydroxybutyrate and acetoacetate. *N Engl J Med*. 1965;272:351-355.
- Gibson HV, Doisy EA. A note on the effect of some organic acids upon the uric acid excretion of man. *J Biol Chem*. 1923;55:605-610.
- Gershon SL, Fox IH. Pharmacologic effects of nicotinic acid on human purine metabolism. *J Lab Clin Med*. 1974;84(2):179-186.
- Shapiro M, Hyde L. Hyperuricemia due to pyrazinamide. *Am J Med*. 1957;23(4):596-599.
- Guggino SE, Aronson PS. Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. *J Clin Invest*. 1985;76(2):543-547.
- Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. *Nature*. 2002;417(6887):447-452.
- Bahn A, Hagos Y, Reuter S, et al. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). *J Biol Chem*. 2008;283(24):16332-16341.
- Hagos Y, Stein D, Ugele B, Burckhardt G, Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. *J Am Soc Nephrol*. 2007;18(2):430-439.
- Manolescu AR, Augustin R, Moley K, Cheeseman C. A highly conserved hydrophobic motif in the exofacial vestibule of fructose transporting SLC2A proteins acts as a critical determinant of their substrate selectivity. *Mol Membr Biol*. 2007;24(5-6):455-463.
- Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. *J Biol Chem*. 2008;283(40):26834-26838.
- Eraly SA, Vallon V, Rieg T, et al. Multiple organic anion transporters contribute to net renal excretion of uric acid. *Physiol Genom*. 2008;33(2):180-192.
- Van Aubel RA, Smeets PH, Van Den Heuvel JJ, Russel FG. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. *Am J Physiol Renal Physiol*. 2005;288(2):F327-F333.
- Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. *Sci Transl Med*. 2009;1(5):5ra11.
- Woodward OM, Kottgen A, Coresh J, Boerwinkle E, Guggino WB, Kottgen M. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. *Proc Natl Acad Sci U S A*. 2009;106(25):10338-10342.
- Iharada M, Miyaji T, Fujimoto T, et al. Type 1 sodium-dependent phosphate transporter (SLC17A1 protein) is a Cl⁻-dependent urate exporter. *J Biol Chem*. 2010;285(34):26107-26113.
- Jutabha P, Kanai Y, Hosoyamada M, et al. Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule. *J Biol Chem*. 2003;278(30):27930-27938.
- Jutabha P, Anzai N, Kitamura K, et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. *J Biol Chem*. 2010;285(45):35123-35132.
- DeBosch BJ, Kluth O, Fujiwara H, Schurmann A, Moley K. Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. *Nat Commun*. 2014;5:4642.
- Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. *Nat Commun*. 2012;3:764.
- Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. *Hypertension*. 2003;42(3):247-252.
- Clifford AJ, Riumallo JA, Youn VR, Scrimshaw NS. Effect of oral purines on serum and urinary uric acid of normal, hyperuricemic and gouty humans. *J Nutr*. 1976;106(3):428-434.
- Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. *Proc Natl Acad Sci U S A*. 1981;78(11):6858-6862.
- Justicia C, Salas-Perdomo A, Perez-de-Puig I, et al. Uric acid is protective after cerebral ischemia/reperfusion in hyperglycemic mice. *Transl Stroke Res*. 2017;8(3):294-305.
- Hooper DC, Spitsin S, Kean RB, et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. *Proc Natl Acad Sci U S A*. 1998;95(2):675-680.
- Imaram W, Gersch C, Kim KM, Johnson RJ, Henderson GN, Angerhofer A. Radicals in the reaction between peroxynitrite and uric acid identified by electron spin resonance spectroscopy and liquid chromatography mass spectrometry. *Free Radic Biol Med*. 2010;49(2):275-281.
- Patricio ES, Prado FM, da Silva RP, et al. Chemical characterization of urate hydroperoxide, a pro-oxidant intermediate generated by urate oxidation in inflammatory and photoinduced processes. *Chem Res Toxicol*. 2015;28(8):1556-1566.
- Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. *Nature*. 2003;425(6957):516-521.

37. Shi Y, Galusha SA, Rock KL. Cutting edge: elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. *J Immunol*. 2006;176(7):3905-3908.
38. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. *Am J Physiol Cell Physiol*. 2007;293(2):C584-C596.
39. Lanaspas MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. *J Biol Chem*. 2012;287(48):40732-40744.
40. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. *J Hypertens*. 2008;26(2):269-275.
41. Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. *J Hypertens*. 2010;28(6):1234-1242.
42. Cirillo P, Gersch MS, Mu W, et al. Ketohehexokinase-dependent metabolism of fructose induces proinflammatory mediators in proximal tubular cells. *J Am Soc Nephrol*. 2009;20(3):545-553.
43. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. *J Am Soc Nephrol*. 2002;13(12):2888-2897.
44. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. *J Am Soc Nephrol*. 2005;16(12):3553-3562.
45. Xiao J, Zhang XL, Fu C, et al. Soluble uric acid increases NALP3 inflammasome and interleukin-1beta expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway. *Int J Mol Med*. 2015;35(5):1347-1354.
46. Zharikov S, Krotova K, Hu H, et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. *Am J Physiol Cell Physiol*. 2008;295(5):C1183-C1190.
47. Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Henderson GN. Inactivation of nitric oxide by uric acid. *Nucleosides Nucleotides Nucleic Acids*. 2008;27(8):967-978.
48. Sanchez-Lozada LG, Lanaspas MA, Cristobal-Garcia M, et al. Uric acid-induced endothelial dysfunction is associated with mitochondrial alterations and decreased intracellular ATP concentrations. *Nephron Exp Nephrol*. 2012;121(3-4):e71-e78.
49. Roncal CA, Mu W, Croker B, et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. *Am J Physiol Renal Physiol*. 2007;292(1):F116-F122.
50. Roncal-Jimenez CA, Lanaspas MA, Rivard CJ, et al. Sucrose induces fatty liver and pancreatic inflammation in male breeder rats independent of excess energy intake. *Metabolism*. 2011;60(9):1259-1270.
51. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. *J Biol Chem*. 1991;266(13):8604-8608.
52. Lanaspas MA, Cicerchi C, Garcia G, et al. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. *PLoS One*. 2012;7(11):e48801.
53. Lanaspas MA, Sanchez-Lozada LG, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. *PLoS One*. 2012;7(10):e47948.
54. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. *Hypertension*. 2001;38(5):1101-1106.
55. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism. *Am J Physiol Renal Physiol*. 2002;282(6):F991-F997.
56. Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. *Am J Physiol Renal Physiol*. 2008;295(4):F1134-F1141.
57. Sanchez-Lozada LG, Tapia E, Lopez-Molina R, et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. *Am J Physiol Renal Physiol*. 2007;292(4):F1238-F1244.
58. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. *Hypertension*. 2002;40(3):355-360.
59. Sanchez-Lozada LG, Tapia E, Santamaria J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. *Kidney Int*. 2005;67(1):237-247.
60. Nakagawa T, Mazzali M, Kang DH, et al. Hyperuricemia causes glomerular hypertrophy in the rat. *Am J Nephrol*. 2003;23(1):2-7.
61. Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link? *J Am Soc Nephrol*. 2005;16(7):1909-1919.
62. Sanchez-Lozada LG, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricemia. *Nephrol Dial Transplant*. 2008;23(4):1179-1185.
63. Sanchez-Lozada LG, Tapia E, Vila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. *Am J Physiol Renal Physiol*. 2002;283(5):F1105-F1110.
64. Sathisha KR, Gopal S, Rangappa KS. Antihyperuricemic effects of thiazidiazolopyrimidin-5-one analogues in oxonate treated rats. *Eur J Pharmacol*. 2016;776:99-105.
65. Sanchez-Lozada LG, Tapia E, Soto V, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. *Nephron Physiol*. 2008;108(4):69-78.
66. Mazzali M, Kim YG, Suga S, et al. Hyperuricemia exacerbates chronic cyclosporine nephropathy. *Transplantation*. 2001;71(7):900-905.
67. Kim HS, Lim SW, Jin L, Jin J, Chung BH, Yang CW. The protective effect of febuxostat on chronic tacrolimus-induced nephrotoxicity in rats. *Nephron*. 2017;135(1):61-71.
68. Mazali FC, Johnson RJ, Mazzali M. Use of uric acid-lowering agents limits experimental cyclosporine nephropathy. *Nephron Exp Nephrol*. 2012;120(1):e12-e19.
69. Lee HJ, Jeong KH, Kim YG, et al. Febuxostat ameliorates diabetic renal injury in a streptozotocin-induced diabetic rat model. *Am J Nephrol*. 2014;40(1):56-63.
70. Komers R, Xu B, Schneider J, Oyama TT. Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes. *Br J Pharmacol*. 2016;173(17):2573-2588.
71. Kim S-M, Lee S-H, Kim Y-G, et al. Hyperuricemia-induced NLRP3 activation of macrophages contributes to the

- progression of diabetic nephropathy. *Am J Physiol Renal Physiol*. 2015;308(9):F993-F1003.
72. Kosugi T, Nakayama T, Heinig M, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. *Am J Physiol Renal Physiol*. 2009;297(2): F481-8.
 73. Laakso JT, Teravainen TL, Martelin E, Vaskonen T, Lapatto R. Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. *J Hypertens*. 2004;22(7):1333-1340.
 74. Gois P, Canale D, Volpini RA, et al. Allopurinol attenuates rhabdomyolysis-associated acute kidney injury: renal and muscular protection. *Free Radic Biol Med*. 2016;101:176-189.
 75. Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. *Clin Exp Nephrol*. 2012;16(4):549-556.
 76. Tsuda H, Kawada N, Kaimori J-y, et al. Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress. *Biochem Biophys Res Commun*. 2012;427(2):266-272.
 77. Martillo MA, Nazzal L, Crittenden DB. The crystallization of monosodium urate. *Curr Rheumatol Rep*. 2014;16(2):400,1-13.
 78. Rock KL, Kataoka H, Lai J-J. Uric acid as a danger signal in gout and its comorbidities. *Nat Rev Rheumatol*. 2012;9(1):13-23.
 79. Kanbay M, Solak Y, Afsar B, et al. Serum uric acid and risk for acute kidney injury following contrast. *Angiology*. 2017;68(2): 132-144.
 80. Roncal-Jimenez C, Garcia-Trabanino R, Barregard L, et al. Heat stress nephropathy from exercise-induced uric acid crystalluria: a perspective on Mesoamerican nephropathy. *Am J Kidney Dis*. 2016;67(1):20-30.
 81. Johnson RJ, Segal MS, Sautin Y, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. *Am J Clin Nutr*. 2007;86(4):899-906.
 82. Choi YJ, Shin HS, Choi HS, et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. *Lab Invest*. 2014;94(10): 1114-1125.
 83. Cicerchi C, Li N, Kratzer J, et al. Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. *FASEB J*. 2014;28(8):3339-3350.
 84. Huang Z, Hong Q, Zhang X, et al. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations. *Cell Commun Signal*. 2017;15(1):1-13.
 85. Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. *Diabetes*. 2011;60(4):1258-1269.
 86. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. *Am J Physiol Renal Physiol*. 2006;290(3):F625-F631.
 87. Reungjui S, Pratipanawatr T, Johnson RJ, Nakagawa T. Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. *Curr Opin Nephrol Hypertens*. 2008;17(5):470-476.
 88. Preitner F, Pimentel A, Metref S, et al. No development of hypertension in the hyperuricemic liver-Glut9 knockout mouse. *Kidney Int*. 2015;87(5):940-947.
 89. Johnson RJ, Andrews P. The fat gene: a genetic mutation in prehistoric apes may underlie today's pandemic of obesity and diabetes. *Sci Am*. 2015;313(4):64-69.
 90. Borghi C, Cicero AFG. Serum uric acid and cardiometabolic disease: another brick in the wall? *Hypertension*. 2017;69(6): 1011-1013.
 91. Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. *J Hypertens*. 2015;33(9): 1729-1741; discussion 1741.
 92. Feig DI, Madero M, Jalal DI, Sanchez-Lozada LG, Johnson RJ. Uric acid and the origins of hypertension. *J Pediatr*. 2013;162(5):896-902.
 93. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. *Arthritis Care Res (Hoboken)*. 2011;63(1):102-110.
 94. Zhang W, Sun K, Yang Y, Zhang H, Hu FB, Hui R. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. *Clin Chem*. 2009;55(11):2026-2034.
 95. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. *Hypertension*. 2005;45(1):18-20.
 96. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. *JAMA*. 2008;300(8):924-932.
 97. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. *Am J Physiol Renal Physiol*. 2004;286(4):F606-F616.
 98. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. *Diabetes*. 2013;62(10):3307-3315.
 99. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. *Diabetes Care*. 2009;32(9):1737-1742.
 100. Lv Q, Meng XF, He FF, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. *PLoS One*. 2013;8(2): e56864.
 101. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. *Hypertension*. 2003;42(4):474-480.
 102. Johnson RJ, Nakagawa T, Jalal D, Sanchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? *Nephrol Dial Transplant*. 2013;28(9): 2221-2228.
 103. Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. *BMC Nephrol*. 2014;15:122.
 104. Zhu P, Liu Y, Han L, Xu G, Ran JM. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies. *PLoS One*. 2014;9(6):e100801.
 105. Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: findings from the Coronary Artery Calcification in Type 1 Diabetes study. *Nephrol Dial Transplant*. 2010;25(6):1865-1869.
 106. Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study. *Diabetes*. 2009;58(7):1668-1671.
 107. De Cosmo S, Viazzi F, Pacilli A, et al. Serum uric acid and risk of CKD in type 2 diabetes. *Clin J Am Soc Nephrol*. 2015;10(11): 1921-1929.
 108. Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. *Am J Kidney Dis*. 2013;61(1):134-146.
 109. Lapsia V, Johnson RJ, Dass B, et al. Elevated uric acid increases the risk for acute kidney injury. *Am J Med*. 2012;125(3):302.e309-302.e317.

110. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? *Hypertension*. 2003;41(6):1183-1190.
111. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. *Arthritis Care Res (Hoboken)*. 2010;62(2):170-180.
112. Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. *PLoS Med*. 2005;2(3):e76.
113. Tangri N, Weiner DE. Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles. *Am J Kidney Dis*. 2010;56(2):247-250.
114. Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic hyperuricemia without comorbidities predicts cardiometabolic diseases: five-year Japanese cohort study. *Hypertension*. 2017;69(6):1036-1044.
115. Odden MC, Amadu AR, Smit E, Lo L, Peralta CA. Uric acid levels, kidney function, and cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES) 1988-1994 and 1999-2002. *Am J Kidney Dis*. 2014;64(4):550-557.
116. Garcia Puig J, Mateos Anton F, Munoz Sanz A, et al. Renal handling of uric acid in normal subjects by means of the pyrazinamide and probenecid tests. *Nephron*. 1983;35(3):183-186.
117. Kottgen A, Albrecht E, Teumer A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nat Genet*. 2013;45(2):145-154.
118. Okada Y, Sim X, Go MJ, et al. Meta-analysis identifies multiple loci associated with kidney function-related traits in east Asian populations. *Nat Genet*. 2012;44(8):904-909.
119. Anzai N, Miyazaki H, Noshiro R, et al. The multivalent PDZ domain-containing protein PDZK1 regulates transport activity of renal urate-anion exchanger URAT1 via its C-terminal. *J Biol Chem*. 2004;279(44):45942-45950.
120. Tin A, Woodward OM, Kao WH, et al. Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele. *Hum Mol Genet*. 2011;20(20):4056-4068.
121. Ichida K, Hosoyamada M, Hisatome I, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan: influence of URAT1 gene on urinary urate excretion. *J Am Soc Nephrol*. 2004;15(1):164-173.
122. Matsuo H, Chiba T, Nagamori S, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. *Am J Hum Genet*. 2008;83(6):744-751.
123. Dinour D, Gray NK, Campbell S, et al. Homozygous SLC2A9 mutations cause severe renal hypouricemia. *J Am Soc Nephrol*. 2010;21(1):64-72.
124. Phipps-Green AJ, Merriman ME, Topless R, et al. Twenty-eight loci that influence serum urate levels: analysis of association with gout. *Ann Rheum Dis*. 2016;75(1):124-130.
125. Urano W, Taniguchi A, Inoue E, et al. Effect of genetic polymorphisms on development of gout. *J Rheumatol*. 2013;40(8):1374-1378.
126. Robinson PC, Choi HK, Do R, Merriman TR. Insight into rheumatological cause and effect through the use of Mendelian randomization. *Nat Rev Rheumatol*. 2016;12(8):486-496.
127. Yang Q, Kottgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. *Circ Cardiovasc Genet*. 2010;3(6):523-530.
128. Sluijs I, Holmes MV, van der Schouw YT, et al. A Mendelian randomization study of circulating uric acid and type 2 diabetes. *Diabetes*. 2015;64(8):3028-3036.
129. Pfister R, Barnes D, Luben R, et al. No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. *Diabetologia*. 2011;54(10):2561-2569.
130. Hughes K, Flynn T, de Zoysa J, Dalbeth N, Merriman TR. Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function. *Kidney Int*. 2014;85(2):344-351.
131. Keenan T, Zhao W, Rasheed A, et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. *J Am Coll Cardiol*. 2016;67(4):407-416.
132. Preitner F, Bonny O, Laverriere A, et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. *Proc Natl Acad Sci U S A*. 2009;106(36):15501-15506.
133. Topless RK, Flynn TJ, Cadzow M, et al. Association of SLC2A9 genotype with phenotypic variability of serum urate in premenopausal women. *Front Genet*. 2015;6:313,1-9.
134. Batt C, Phipps-Green AJ, Black MA, et al. Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout. *Ann Rheum Dis*. 2014;73(12):2101-2106.
135. Scheepers LE, Wei FF, Stolarz-Skrzypiec K, et al. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. *J Hypertens*. 2016;34(11):2147-2154.
136. Yang J, Kamide K, Kokubo Y, et al. Associations of hypertension and its complications with variations in the xanthine dehydrogenase gene. *Hypertens Res*. 2008;31(5):931-940.
137. Kleber ME, Delgado G, Grammer TB, et al. Uric acid and cardiovascular events: a Mendelian randomization study. *J Am Soc Nephrol*. 2015;26(11):2831-2838.
138. Testa A, Mallamaci F, Leonardis D, et al. Synergism between asymmetric dimethylarginine (ADMA) and a genetic marker of uric acid in CKD progression. *Nutr Metab Cardiovasc Dis*. 2015;25(2):167-172.
139. Voruganti VS, Laston S, Haack K, et al. Serum uric acid concentrations and SLC2A9 genetic variation in Hispanic children: the Viva La Familia Study. *Am J Clin Nutr*. 2015;101(4):725-732.
140. Voruganti VS, Nath SD, Cole SA, et al. Genetics of variation in serum uric acid and cardiovascular risk factors in Mexican Americans. *J Clin Endocrinol Metab*. 2009;94(2):632-638.
141. Sun X, Zhang R, Jiang F, et al. Common variants related to serum uric acid concentrations are associated with glucose metabolism and insulin secretion in a Chinese population. *PLoS One*. 2015;10(1):e0116714.
142. Shafiu M, Johnson RJ, Turner ST, et al. Urate transporter gene SLC22A12 polymorphisms associated with obesity and metabolic syndrome in Caucasians with hypertension. *Kidney Blood Press Res*. 2012;35(6):477-482.
143. Parsa A, Brown E, Weir MR, et al. Genotype-based changes in serum uric acid affect blood pressure. *Kidney Int*. 2012;81(5):502-507.
144. Mallamaci F, Testa A, Leonardis D, et al. A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family-based study. *Am J Kidney Dis*. 2015;65(2):294-302.
145. Mallamaci F, Testa A, Leonardis D, et al. A polymorphism in the major gene regulating serum uric acid associates with clinic SBP and the white-coat effect in a family-based study. *J Hypertens*. 2014;32(8):1621-1628.

146. Voruganti VS, Franceschini N, Haack K, et al. Replication of the effect of SLC2A9 genetic variation on serum uric acid levels in American Indians. *Eur J Hum Genet.* 2014;22(7):938-943.
147. Palmer TM, Nordestgaard BG, Benn M, et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts. *BMJ.* 2013;347:f4262.
148. Pattaro C, Teumer A, Gorski M, et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. *Nat Commun.* 2016;7:10023.
149. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. *Hypertension.* 2012;60(5):1148-1156.
150. Higgins P, Walters MR, Murray HM, et al. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. *Heart.* 2014;100(14):1085-1092.
151. Madero M, Rodriguez Castellanos FE, Jalal D, et al. A pilot study on the impact of a low fructose diet and allopurinol on clinic blood pressure among overweight and prehypertensive subjects: a randomized placebo controlled trial. *J Am Soc Hypertens.* 2015;9(11):837-844.
152. Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. *Clin J Am Soc Nephrol.* 2011;6(8):1887-1894.
153. Borgi L, McMullan C, Wohlhueter A, Curhan GC, Fisher ND, Forman JP. Effect of uric acid-lowering agents on endothelial function: a randomized, double-blind, placebo-controlled trial. *Hypertension.* 2017;69(2):243-248.
154. McMullan CJ, Borgi L, Fisher N, Curhan G, Forman J. Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial. *Clin J Am Soc Nephrol.* 2017;12(5):807-816.
155. Segal MS, Srinivas TR, Mohandas R, et al. The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic. *J Am Soc Hypertens.* 2015;9(8):610-619.e611.
156. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. *Am J Kidney Dis.* 2006;47(1):51-59.
157. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. *Clin J Am Soc Nephrol.* 2010;5(8):1388-1393.
158. Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. *Am J Kidney Dis.* 2015;66(6):945-950.
159. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. *J Clin Rheumatol.* 2011;17(1):7-13.
160. Kim HA, Seo YI, Song YW. Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men. *J Korean Med Sci.* 2014;29(8):1077-1081.
161. Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. *Clin Endocrinol (Oxf).* 2015;83(4):475-482.
162. Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. *Am J Kidney Dis.* 2015;65(4):543-549.
163. Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). *Circ J.* 2013;77(8):2043-2049.
164. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. *Iran J Kidney Dis.* 2010;4(2):128-132.
165. Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial. *Kidney Blood Press Res.* 2012;35(3):153-160.
166. Tanaka K, Nakayama M, Kanno M, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. *Clin Exp Nephrol.* 2015;19(6):1044-1053.
167. Ejaz AA, Dass B, Lingegowda V, et al. Effect of uric acid lowering therapy on the prevention of acute kidney injury in cardiovascular surgery. *Int Urol Nephrol.* 2013;45(2):449-458.
168. Kumar S, Bhawani G, Kumari N, Murthy KSN, Lalwani V, Raju CHN. Comparative study of renal protective effects of allopurinol and N-acetyl-cysteine on contrast induced nephropathy in patients undergoing cardiac catheterization. *J Clin Diagn Res.* 2014;8(12):HC03-HC07.
169. Erol T, Tekin A, Katircibasi MT, et al. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. *Int J Cardiol.* 2013;167(4):1396-1399.
170. Ogino K, Kato M, Furuse Y, et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. *Circ Heart Fail.* 2010;3(1):73-81.
171. Meng J, Li Y, Yuan X, Lu Y. Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. *Rheumatol Int.* 2017;37(2):299-303.
172. Takir M, Kostek O, Ozkok A, et al. Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia. *J Investig Med.* 2015;63(8):924-929.
173. Perez-Pozo SE, Schold J, Nakagawa T, Sanchez-Lozada LG, Johnson RJ, Lillo JL. Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response. *Int J Obes (Lond).* 2010;34(3):454-461.
174. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. *Circulation.* 2006;114(23):2508-2516.
175. McNally JS, Davis ME, Giddens DP, et al. Role of xanthine oxidoreductase and NAD(P)H oxidase in endothelial superoxide production in response to oscillatory shear stress. *Am J Physiol Heart Circ Physiol.* 2003;285(6):H2290-H2297.
176. Talaat KM, El-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. *Am J Nephrol.* 2007;27(5):435-440.
177. Jung JW, Song WJ, Kim YS, et al. HLA-B*58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. *Nephrol Dial Transplant.* 2011;26(11):3567-3572.

178. MacDonald TM, Ford I, Nuki G, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. *BMJ Open*. 2014;4(7):e005354.
179. FDA. Uloric (febuxostat): Drug Safety Communication - FDA to evaluate increased risk of heart-related death. 2017. <https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm585281.htm>. Accessed November 23, 2017.
180. Sanchez-Nino MD, Zheng-Lin B, Valino-Rivas L, et al. Lesinurad: what the nephrologist should know. *Clin Kidney J*. 2017;10(5):679-687.
181. Maahs DM, Caramori L, Cherney DZ, et al. Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study. *Curr Diab Rep*. 2013;13(4):550-559.
182. Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. *Cochrane Database Syst Rev*. 2017;10:CD009460.